52North raised €6 million in a funding round co-led by KHP Ventures and Cedars-Sinai IP Co. to advance oncology-focused innovations and bring Neutrocheck® to market.
Jonathan MilnerRoland DiggelmannOkg CapitalCambridge Enterprise VenturesCancer Research HorizonsMacmillan Cancer SupportKHP VenturesCedars Sinai Intellectual Property Co.
Description
52North, a UK med-tech startup, secured €6 million in a funding round co-led by KHP Ventures and Cedars-Sinai Intellectual Property Co. This funding will help expand their product pipeline and enhance their offerings in oncology care, particularly through their Neutrocheck® device.
Who to call at 52North, and when
A new round usually means 52North is about to hire and buy. The teams that reach out first get the meeting.
An alert the day 52North raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at 52North, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at 52North. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
52North
Location
Cambridge, England, United Kingdom
About
52North is a UK med-tech startup focused on oncological advancements. The company offers innovative solutions such as Neutrocheck®, a point-of-care device designed to monitor patients undergoing chemotherapy. With the goal of improving patient care, 52North aims to leverage AI and collaborations to enhance acute oncology care delivery. Their ongoing efforts are supported by strategic partners and healthcare leaders from both the UK and US.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment 52North raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CambridgeBiotechnologyHealth CareMedicalMedical Device